Question 1

What is Johan Sandin?

Accepted Answer

Johan Sandin is a Person.

Question 2

How often does Johan Sandin appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Johan Sandin first tracked by Ergen?

Accepted Answer

First tracked on Apr 20, 2026.

Question 4

When was Johan Sandin last mentioned in news?

Accepted Answer

Last active on Jul 01, 2026.

Question 5

What is Johan Sandin's current news sentiment?

Accepted Answer

Aggregate sentiment score: 30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Johan Sandin in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Johan Sandin?

Accepted Answer

AlzeCure Pharma completes ACD856 Phase Ib (Apr 20, 2026, 6 articles).

Question 8

How did the "AlzeCure Pharma completes ACD856 Phase Ib" event impact Johan Sandin?

Accepted Answer

Johan Sandin, CSO at AlzeCure Pharma, provided commentary on the strong safety and tolerability profile of ACD856 and its potential for wider therapeutic applications.

Question 9

How did the "AlzeCure Pharma licenses NeuroRestore to QuantumCell" event impact Johan Sandin?

Accepted Answer

Johan Sandin, Chief Scientific Officer at AlzeCure Pharma, provided commentary on the potential of ACD856, highlighting its broad indications.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.